Hipofiz Adenomu Olan Bir Hastada Sertralin Kullanımına Bağlı Prolaktin Yüksekliği: Bir Olgu Sunumu

Yıl 2024, , 121 - 125, 29.04.2024

Meltem Puşuroğlu , Sefanur Köse , Cicek Hocaoglu

https://doi.org/10.46332/aemj.1217431

Öz

Antipsikotikler psikiyatri ilaç grupları arasında en sık prolaktinemiye yol açan ilaç grubudur. Prolaktin yüksekliği genellikle antipsi- kotiklere bağlı bir yan etki olarak düşünülmektedir. Ancak klinikte antidepresan kullanımına bağlı prolaktin yüksekliği de gözlenmek- tedir. İlaçların sebep olduğu prolaktin yüksekliğini belirlemek ve tedavi seçeneklerini gözden geçirmek önemlidir. Olgumuzda hipofiz adenomu olan bir hastada sertralin kullanımı sonrasında prolaktin yüksekliği bildirilmiştir. Hastanın adenomu olmasına rağmen prolaktin yüksekliğinin nedeni sertralin kullanımı olarak görülmüştür. Prolaktin yüksekliği ile başvuran bir hastada kullandığı ilaçlar ve prolaktin düzeyine olan etkisi ilk değerlendirilmesi gereken konulardan biridir.

Anahtar Kelimeler

galaktore, prolaktinemi, yan etki

Destekleyen Kurum

destekleyen kurum yoktur

Prolactin Elevation Due to Sertraline Use in a Patient with Pituitary Adenoma: A Case Report

Öz

Antipsychotics are the drugs that most frequently cause prolactinemia among the psychiatric drug groups. When prolactin eleva tion is mentioned, it is generally considered as a side effect related to antipsychotics. However, prolactin elevation is also observed in the clinic due to the use of antidepressants. It is important to identify prolactinoma via drugs and to review treatment options. In our case, prolactin elevation of patient with pituitary adenoma was reported after the use of sertraline. Although the patient had adenoma, sertraline was found to be the cause of elevated prolactin. In a patient presenting with elevated prolactin, medications and their effect on prolactin levels are among the first issues to be evaluated.

Anahtar Kelimeler

galactorrhea, prolactinemia, side effects

Kaynakça

• 1. Thapa S, Bhusal K. Hyperprolactinemia. USA: StatPearls Publishing;2019.
• 2. Ciccarelli A, Guerra E, De Rosa M, et al. PRL secreting adenomas in male patients. Pituitary. 2005;8(1):39-42.
• 3. Molitch ME. Drugs and prolactin. Pituitary. 2008;11(2):209-218.
• 4. Chen JX, Su YA, Bian QT, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130-140.
• 5. Ekinci N, Günes S, Kalinli M, Ekinci Ö. Sertraline-Related Amenorrhea in an Adolescent. Clin. Neuropharmacol. 2019;42(3):99-100.
• 6. Wessels-van Middendorp AM, Timmerman L. Galactorrhoea and the use of selective serotonin reuptake inhibitors. Tijdschr. Psychiatr. 2006;48(3):229-234.
• 7. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry. 1993;150(8):1269-1270.
• 8. Bulut SD, Tüzer V, Bulut S, Göka E. Essitalopram ile Gelişen Hiperprolaktinemi Olgusu: Ketiapin Kullanımı Bir Seçenek Olabilir mi? Klın Psıkofarmakol B. 2009;19:272-274.
• 9. Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr. Res. 1999;35:67-73.
• 10. Damsa C, Bumb A, Bianchi-Demicheli F, et al. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry. 2004;65(8):1064-1068.
• 11. Park Y-M. Serum prolactin levels in patients with major depressive disorder receiving selective serotonin-reuptake inhibitor monotherapy for 3 months: a prospective study. Psychiatry Investig. 2017;14(3):368.
• 12. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5): 929-951.
• 13. Cortet-Rudelli C, Sapin R, Bonneville JF, Brue T. Etiological diagnosis of hyperprolactinemia. Ann. Endocrinol. 2007;68(2-3):98-105.
• 14. Melgar V, Espinosa E, Sosa E, et al. Current diagnosis and treatment of hyperprolactinemia. Rev Med Inst Mex Seguro Soc. 2016;54(1):111-121.
• 15. Güzel Ö, Atan A, Aslan Y. Hiperprolaktinemi ve erektil disfonksiyon. Androl Bul. 2018;20(3):90-94.
• 16. Luciano AA. Clinical presentation of hyperprolactinemia. J Reprod Med. 1999;44(12): 1085-1090.
• 17. Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol. Endocrinol. 2015;31(7):506-510.
• 18. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug safety. 1999;20(3):277-287.
• 19. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999;57(4):507-533.
• 20. Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29-36.
• 21. Verhelst J, Abs R. Hyperprolactinemia: pathophysiology and management. Treatments in endocrinology. 2003;2(1):23-32.